ADIPOQ and coronary artery disorder: We have previously shown that chronic exposure (16–20 h) to adiponectin, or a nonselective adiponectin receptor agonist (AdipoRON), is capable of restoring NO-mediated FID in human microvessels collected from patients diagnosed with CAD (Schulz et al., 2019).